Product Information
| Property | Description |
|---|---|
| Product Name | Anti-mouse/human NF2 / Merlin Recombinant Monoclonal Antibody |
| Antibody ID | XM0039 |
| Target Protein | Merlin / NF2 |
| UniProt Accession | Human: P35240-1, P35240-2, P35240-3, P35240-4, P35240-5, P35240-6, P35240-7, P35240-8, P35240-9, P35240-10; Mouse: P46662-1, P46662-2 |
| Molecular Weight | Human isoforms: 19.2–72.5 kDa; Mouse isoforms: 69.2–69.8 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Mouse and human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | MAGAIASRMSFSSLKRKQPK |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
Merlin, also known as Neurofibromin 2 (NF2), is a tumor suppressor protein involved in cytoskeletal organization, membrane dynamics, contact inhibition, Hippo signaling, and regulation of cell proliferation. Merlin plays an essential role in tumor suppression and cellular signaling and is widely studied in neurofibromatosis type 2, cancer biology, nervous system biology, and cytoskeleton-related signaling pathways.
Because Merlin regulates multiple growth-control pathways, it is an important target in cancer and translational research.
Antibody Development
XM0039 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the Merlin epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous Merlin protein in mouse tissues
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length Merlin protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while no significant binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous Merlin protein in mouse brain and liver tissues under reducing conditions.
Validated samples:
- Mouse brain tissue
- Mouse liver tissue
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Major bands observed near expected Merlin molecular weights
- Additional lower molecular weight bands may represent isoforms or processed protein species















